CN113144107A - Traditional Chinese medicine for treating lung cancer and preparation method thereof - Google Patents
Traditional Chinese medicine for treating lung cancer and preparation method thereof Download PDFInfo
- Publication number
- CN113144107A CN113144107A CN202010451795.3A CN202010451795A CN113144107A CN 113144107 A CN113144107 A CN 113144107A CN 202010451795 A CN202010451795 A CN 202010451795A CN 113144107 A CN113144107 A CN 113144107A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- broken
- wall
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 34
- 208000020816 lung neoplasm Diseases 0.000 title claims abstract description 21
- 206010058467 Lung neoplasm malignant Diseases 0.000 title claims abstract description 20
- 201000005202 lung cancer Diseases 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000000843 powder Substances 0.000 claims abstract description 35
- 241000222336 Ganoderma Species 0.000 claims abstract description 27
- 239000000284 extract Substances 0.000 claims abstract description 24
- 235000015489 Emblica officinalis Nutrition 0.000 claims abstract description 17
- 241000219068 Actinidia Species 0.000 claims abstract description 16
- 241000218176 Corydalis Species 0.000 claims abstract description 16
- 241001149649 Taxus wallichiana var. chinensis Species 0.000 claims abstract description 14
- 241000031023 Amana edulis Species 0.000 claims abstract description 12
- 235000014676 Phragmites communis Nutrition 0.000 claims abstract description 11
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims abstract description 11
- 235000011613 Pinus brutia Nutrition 0.000 claims abstract description 11
- 241000018646 Pinus brutia Species 0.000 claims abstract description 11
- 240000009120 Phyllanthus emblica Species 0.000 claims abstract 2
- 244000119298 Emblica officinalis Species 0.000 claims description 15
- 235000013399 edible fruits Nutrition 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 241001250596 Pleione Species 0.000 claims description 3
- 239000009609 fructus phyllanthi Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 24
- 230000000694 effects Effects 0.000 description 19
- 210000004881 tumor cell Anatomy 0.000 description 14
- 230000002401 inhibitory effect Effects 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 8
- 230000036039 immunity Effects 0.000 description 8
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 238000001959 radiotherapy Methods 0.000 description 5
- 230000001093 anti-cancer Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 240000008397 Ganoderma lucidum Species 0.000 description 3
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 229930003944 flavone Natural products 0.000 description 3
- 150000002212 flavone derivatives Chemical class 0.000 description 3
- 235000011949 flavones Nutrition 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 3
- 244000298715 Actinidia chinensis Species 0.000 description 2
- 235000009434 Actinidia chinensis Nutrition 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000002091 Febrile Seizures Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002024 ethyl acetate extract Substances 0.000 description 2
- 206010016284 febrile convulsion Diseases 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000131329 Carabidae Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 102000010970 Connexin Human genes 0.000 description 1
- 108050001175 Connexin Proteins 0.000 description 1
- 102000001045 Connexin 43 Human genes 0.000 description 1
- 108010069241 Connexin 43 Proteins 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 206010061968 Gastric neoplasm Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- 150000004008 N-nitroso compounds Chemical class 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241001116500 Taxus Species 0.000 description 1
- 241000508252 Taxus mairei Species 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000000719 anti-leukaemic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 231100000005 chromosome aberration Toxicity 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 208000003512 furunculosis Diseases 0.000 description 1
- 210000003976 gap junction Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000005550 inflammation mediator Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- JWDFWIZNGSOUGC-INIZCTEOSA-N n-[(7s)-10-amino-1,2,3-trimethoxy-9-oxo-6,7-dihydro-5h-benzo[a]heptalen-7-yl]acetamide Chemical class C1([C@@H](NC(C)=O)CC2)=CC(=O)C(N)=CC=C1C1=C2C=C(OC)C(OC)=C1OC JWDFWIZNGSOUGC-INIZCTEOSA-N 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a traditional Chinese medicine for treating lung cancer and a preparation method thereof, wherein the traditional Chinese medicine comprises the following components: the Chinese medicine composition comprises radix tetrastigme powder, lucid ganoderma extract, wall-broken lucid ganoderma spore powder, wall-broken pine pollen, taxus chinensis var mairei, edible tulip, Chinese actinidia root, corydalis amabilis, phyllanthus emblica and reed rhizome.
Description
Technical Field
The invention relates to the field of traditional Chinese medicines, in particular to a traditional Chinese medicine for treating lung cancer and a preparation method thereof.
Background
The traditional Chinese medicine is one of the essentials which are passed down in thousands of years in China, is a unique tradition of China, the whole system comprises a prescription, Chinese herbal medicines and a production process, the Chinese herbal medicines can be drunk only by decocting for a certain duration and time, the Chinese herbal medicines are hundreds of and thousands of, and different categories have different curative effects, but China is still lack of a good traditional Chinese medicine formula in the aspect of treating tumors, particularly high-incidence lung cancer, and as is well known, the incidence of lung cancer always ranks first in China, besides radiotherapy and chemotherapy and targeted therapy adopted in modern hospitals, the subsequent treatment is the first choice of traditional Chinese medicine, but at present, the modern medicine generally considers that the traditional Chinese medicine is used for assisting western medicine treatment, and in most cases, the traditional Chinese medicine is used for assisting treatment, particularly, the immunity improvement after radiotherapy and chemotherapy is preferred, but most of traditional Chinese medicines on the market have treatment effects in publicity.
Disclosure of Invention
The invention aims to solve the technical problem of providing the traditional Chinese medicine for treating the lung cancer, which has good effects of assisting and improving the immunity after radiotherapy and chemotherapy and has the effects of strengthening the body resistance, consolidating the constitution and inhibiting tumor cells.
In order to solve the problems, the invention adopts the following technical scheme: a traditional Chinese medicine for treating lung cancer comprises the following components: radix tetrastigme powder, lucid ganoderma extract, wall-broken lucid ganoderma spore powder, wall-broken pine pollen, taxus chinensis var mairei, edible tulip, Chinese actinidia root, corydalis amabilis, phyllanthus emblica and reed rhizome.
Further, the Chinese medicinal materials comprise the following components in percentage by mass: the traditional Chinese medicine comprises the following components in percentage by mass: 20-30 parts of radix tetrastigme powder, 5-8 parts of lucid ganoderma extract, 5-8 parts of wall-broken lucid ganoderma spore powder, 4-6 parts of wall-broken pine pollen, 10-13 parts of taxus chinensis var mairei, 8-12 parts of edible tulip, 8-13 parts of Chinese actinidia root, 5-10 parts of corydalis amabilis, 5-8 parts of emblic leafflower fruit and 10-13 parts of reed rhizome.
Further, the Chinese medicinal materials comprise the following components in percentage by mass: 27 parts of radix tetrastigme powder, 6 parts of lucid ganoderma extract, 7 parts of wall-broken lucid ganoderma spore powder, 6 parts of wall-broken pine pollen, 10 parts of taxus chinensis, 10 parts of edible tulip, 10 parts of Chinese actinidia root, 8 parts of corydalis amabilis, 6 parts of emblic leafflower fruit and 10 parts of reed rhizome.
A preparation method of a traditional Chinese medicine for treating lung cancer comprises the following steps:
1) decocting Taxus chinensis var mairei, Pseudobulbus Cremastrae seu pleiones, radix Actinidiae chinensis, rhizoma corydalis Decumbentis, fructus Phyllanthi, and rhizoma Phragmitis for 2 times, and collecting decoction;
2) mixing the decoctions obtained by 2 times, and concentrating to obtain extract;
3) mixing the extracts with 4 powders of radix Apioris Fortunei powder, Ganoderma extract, cell wall-broken Ganoderma spore powder, and cell wall-broken pollen Pini, and making into pill.
The invention has the beneficial effects that: the traditional Chinese medicine bag for treating lung cancer comprises radix tetrastigme powder, a lucid ganoderma extract, wall-broken lucid ganoderma spore powder, wall-broken pine pollen, taxus chinensis, edible tulip, actinidia chinensis root, corydalis amabilis, phyllanthus emblica and reed rhizome, and the adopted traditional Chinese medicine components have the effects of improving immunity and inhibiting tumor cells, particularly the radix tetrastigme powder is found to have good effects of treating lung diseases and inhibiting disease development through careful research.
Detailed Description
The following detailed description of the preferred embodiments of the present invention is provided to enable those skilled in the art to more readily understand the advantages and features of the present invention and to clearly and unequivocally define the scope of the present invention.
Example one
A traditional Chinese medicine for treating lung cancer comprises the following components: 20 parts of radix tetrastigme powder, 8 parts of lucid ganoderma extract, 8 parts of wall-broken lucid ganoderma spore powder, 6 parts of wall-broken pine pollen, 12 parts of taxus chinensis, 10 parts of edible tulip, 12 parts of Chinese actinidia root, 8 parts of corydalis amabilis, 5 parts of emblic leafflower fruit and 11 parts of reed rhizome.
Example two
A traditional Chinese medicine for treating lung cancer comprises the following components: 27 parts of radix tetrastigme powder, 6 parts of lucid ganoderma extract, 7 parts of wall-broken lucid ganoderma spore powder, 6 parts of wall-broken pine pollen, 10 parts of taxus chinensis, 10 parts of edible tulip, 10 parts of Chinese actinidia root, 8 parts of corydalis amabilis, 6 parts of emblic leafflower fruit and 10 parts of reed rhizome.
EXAMPLE III
A traditional Chinese medicine for treating lung cancer comprises the following components: 30 parts of radix tetrastigme powder, 5 parts of lucid ganoderma extract, 6 parts of wall-broken lucid ganoderma spore powder, 5 parts of wall-broken pine pollen, 10 parts of taxus chinensis, 10 parts of edible tulip, 10 parts of Chinese actinidia root, 8 parts of corydalis amabilis, 6 parts of emblic leafflower fruit and 10 parts of reed rhizome.
Wall-broken ganoderma lucidum spore powder:
(1) the anticancer effect is as follows: the ganoderma lucidum spore powder can destroy cancer cell telomerase by 1005; directly stimulate the proliferation of lymphocytes, antagonize and inhibit the growth and spread of cancer cells; inhibiting cell chromosome aberration, inhibiting generation of tumor cell free radicals, and protecting DNA; inhibiting the destruction of tumor cells to surrounding tissues and the growth of tumor cells; improving the tolerance of tumor patients to radiotherapy, chemotherapy and operation.
(2) Immunization: the Ganoderma spore powder can activate phagocytic function of macrophage, and has antagonistic effect on glucocorticoid; can improve the proliferation capacity of spleen lymphocytes, improve the activity of NK cells, improve the anti-volume numerical value of serum hemolysin and improve the phagocytosis rate of macrophages! It is indicated that it has effect in enhancing immunity.
Curative effect of ganoderma lucidum spore powder with lower surface wall breaking for improving subjective symptoms of cancer patients undergoing radiotherapy and chemotherapy
Radix tetrastigme powder: radix tetrastigme is listed as an endangered rare species in national medical treasury and has the effects of resisting inflammation, viruses, tumors and the like. Has unique curative effect on various heat symptoms (febrile convulsion, fever of unknown reason) and various edemas (inflammatory edema and traumatic injury), and is a 'plant antibiotic' which can not be replaced by western medicines. Poetry is the evidence: febrile convulsion with marked wonder, viral inflammation with no trace; treating hepatitis, brain lymph nodes, furunculosis, snake injury, and traumatic injury. Radix Apioris Fortunei contains radix Apioris Fortunei flavone, and the material has anti-inflammatory, antipyretic and anti-tumor effects. The active ingredients of radix tetrastigme comprise alkaloid, reducing sugar, amino acid, quercetin, kaempferol and flavonoid substances.
(1) Anti-tumor effect
The radix tetrastigme flavone can obviously inhibit the growth of SGC-7901 gastric cancer cells and SMM C-7721 liver cancer cells; the radix tetrastigme extract can inhibit the proliferation of human colon cancer HT-29 cells, HepG2 cells, lung cancer cells A549, human colon cancer cell lines RKO cells, leukemia K562 cells and leukemia HL60 cells.
Tests prove that the golden silk and ground beetle capsule which takes the radix tetrastigme as the main component has obvious effects on inhibiting the growth of Lewis lung tumor cells, SMMC-7721 liver tumor cells, HL-60 human lymphoblastic leukemia cells, SCG-7901 stomach tumor cells and HCT-116 colon tumor cells.
(2) Regulating immunity
The radix tetrastigme extract has effect in correcting intestinal tract local and systemic immunity disorder caused by scald. The radix tetrastigme can also obviously improve the immune function of mice and indexes of TNF-Ot (serum tumor necrosis factor-01) and IFN-y (haemointerferon-1), and the ethyl acetate extract of the radix tetrastigme can regulate the immune function of I-CR mice.
Weikemin professor obtained from Wuyi labour medal of China of national grade famous traditional Chinese medicine of Zhejiang institute of traditional Chinese medicine completes experimental research on anti-tumor action mechanism of radix tetrastigme of traditional Chinese medicine based on the administration of traditional Chinese medicine in Zhejiang province for eight years. Clinical observation is carried out on 120 malignant tumor patients taking the radix tetrastigme preparation from 3 months 2006 to 3 months 2007, and the curative effect is judged. The statistics of the therapeutic effect judgment standard of the World Health Organization (WHO) on malignant tumors are referred to: 120 malignant tumor patients, the radix tetrastigme preparation is orally taken for 90 days, 52 cases are completely relieved, 42 cases are partially relieved, 18 cases are stabilized, 8 cases are progressed, 94 cases are relieved and partially relieved, and the total effective rate is 78.33%.
Emblic leafflower fruit: (1) the anti-cancer effect is as follows: the emblic leafflower fruit extract can block the synthesis of a strong carcinogen N-nitroso compound in vivo or in vitro, the blocking rate is over 90 percent and is 3 to 5 times higher than that of Vc with the same concentration, and the emblic leafflower fruit extract has an anti-cancer effect. The phenolic acid component of the emblic leafflower fruit can inhibit the proliferation of a human cancer cell strain K562 in vitro.
Anti-inflammatory action: the emblic leafflower fruit can obviously inhibit the agar footpad swelling of a rat and the ear rim swelling of the mouse caused by dimethylbenzene, and obviously inhibit the capillary permeability enhancement and the leucocyte exudation caused by histamine, which shows that the emblic leafflower fruit has obvious anti-inflammatory and anti-exudation effects, and the anti-inflammatory effect is enhanced along with the increase of the dosage.
Rhizoma corydalis Decumbentis powder: the analgesic effect is as follows: rhizoma corydalis Decumbentis has significant analgesic and anti-inflammatory effects on pain caused by chemical stimulation and electrical stimulation: rhizoma corydalis Decumbentis has good inhibitory effects on rat plantar inflammation caused by carrageenan and egg white, mouse ear shell swelling caused by xylene and rat subcutaneous paper granuloma hyperplasia, and has good anti-inflammatory effects.
And (3) taxus mairei: (1) wide antitumor effect: experiments prove that the taxol can reduce the tumor incidence, interfere the metabolism of tumor cells, inhibit the proliferation of the tumor cells and induce the death of the tumor cells. (2) Taxol also has anti-leukemia effect. (2) Enhancing the immunity of the organism: the alkaloid can improve sleep; the yew flavone can improve peripheral blood T lymphocyte activity, enhance NK cell killing ability, thereby enhancing organism immunity and improving anticancer effect. (4) Diminishing inflammation and easing pain: a large amount of tannin in Taxus chinensis can reduce inflammation mediator release, improve complicated inflammation of cancer patients, and relieve pain.
And (3) edible tulip: the anti-tumor effect is as follows: col in Pseudobulbus Cremastrae Seu pleiones and its colchicamide derivative have inhibitory effect on various animal transplantation tumors.
Chinese actinidia root: modern pharmacological research shows that the Chinese actinidia root has an inhibiting effect on the growth of various tumor cells, and the extract of the Chinese actinidia root has obvious antitumor activity. Li Shi et al, show that it has strong inhibitory effect on gastric cancer cells by using an ethyl acetate extract of Actinidia chinensis planch root and adopting MTT method research. Studies of Sunshi, etc. find that the extract of radix Actinidiae chinensis with ethyl acetate has the effect of inhibiting lung cancer in vivo and in vitro. Studies such as Zhang's and the like show that after 3 drug concentrations of the n-butyl alcohol extract of the Chinese actinidia root act on 24 h, 48 h and 72h of Eca-109 cells, obvious apoptosis characteristics are displayed. Bellevis and the like have studied on cervical cancer cell lines Hela, neurotumor cell lines NG10815, gastric cancer cell lines SG7901 and the like which act on the Chinese actinidia roots by adopting methods such as an MTT colorimetric method, a colony formation method and the like, and as a result, the Chinese actinidia roots have different degrees of inhibition effects on the growth of different tumor cells. Yao's et al have discussed the growth of high metastatic human lung cancer cell (PG) and influence of expression level of protein Cx43 of the gap junction of cells of compound radix Actinidiae chinensis preparation, the result indicates, compound radix Actinidiae chinensis preparation PG cell has growth inhibiting effects.
The above description is only for the specific embodiment of the present invention, but the protection scope of the present invention is not limited thereto, and any changes or substitutions that are not thought of through the inventive work should be covered by the protection scope of the present invention.
Claims (4)
1. A traditional Chinese medicine for treating lung cancer is characterized in that: the traditional Chinese medicine comprises the following components: radix tetrastigme powder, lucid ganoderma extract, wall-broken lucid ganoderma spore powder, wall-broken pine pollen, taxus chinensis var mairei, edible tulip, Chinese actinidia root, corydalis amabilis, phyllanthus emblica and reed rhizome.
2. The traditional Chinese medicine for treating lung cancer and the preparation method thereof according to claim 1, wherein the traditional Chinese medicine is characterized in that: the traditional Chinese medicine comprises the following components in percentage by mass: 20-30 parts of radix tetrastigme powder, 5-8 parts of lucid ganoderma extract, 5-8 parts of wall-broken lucid ganoderma spore powder, 4-6 parts of wall-broken pine pollen, 10-13 parts of taxus chinensis var mairei, 8-12 parts of edible tulip, 8-13 parts of Chinese actinidia root, 5-10 parts of corydalis amabilis, 5-8 parts of emblic leafflower fruit and 10-13 parts of reed rhizome.
3. The traditional Chinese medicine for treating lung cancer and the preparation method thereof according to claim 2, characterized in that: the traditional Chinese medicinal materials comprise the following components in percentage by mass: 27 parts of radix tetrastigme powder, 6 parts of lucid ganoderma extract, 7 parts of wall-broken lucid ganoderma spore powder, 6 parts of wall-broken pine pollen, 10 parts of taxus chinensis, 10 parts of edible tulip, 10 parts of Chinese actinidia root, 8 parts of corydalis amabilis, 6 parts of emblic leafflower fruit and 10 parts of reed rhizome.
4. The preparation method of the traditional Chinese medicine for treating lung cancer according to claim 1, characterized in that: the method comprises the following steps:
1) decocting Taxus chinensis var mairei, Pseudobulbus Cremastrae seu pleiones, radix Actinidiae chinensis, rhizoma corydalis Decumbentis, fructus Phyllanthi, and rhizoma Phragmitis for 2 times, and collecting decoction;
2) mixing the decoctions obtained by 2 times, and concentrating to obtain extract;
3) mixing the extracts with 4 powders of radix Apioris Fortunei powder, Ganoderma extract, cell wall-broken Ganoderma spore powder, and cell wall-broken pollen Pini, and making into pill.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010451795.3A CN113144107A (en) | 2020-05-25 | 2020-05-25 | Traditional Chinese medicine for treating lung cancer and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010451795.3A CN113144107A (en) | 2020-05-25 | 2020-05-25 | Traditional Chinese medicine for treating lung cancer and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113144107A true CN113144107A (en) | 2021-07-23 |
Family
ID=76882136
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010451795.3A Pending CN113144107A (en) | 2020-05-25 | 2020-05-25 | Traditional Chinese medicine for treating lung cancer and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113144107A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113599460A (en) * | 2021-09-24 | 2021-11-05 | 广州颐寿达生物科技有限公司 | Ganoderma lucidum composition for assisting in inhibiting tumors and preparation method thereof |
CN114272308A (en) * | 2022-02-19 | 2022-04-05 | 姚远平 | A Chinese medicinal composition for treating cancer, and its preparation method |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107334807A (en) * | 2017-07-14 | 2017-11-10 | 武夷山元生泰生物科技有限公司 | A kind of ganoderma lucidum radix tetrastigme pulvis with treatment lung cancer effect and preparation method thereof |
-
2020
- 2020-05-25 CN CN202010451795.3A patent/CN113144107A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107334807A (en) * | 2017-07-14 | 2017-11-10 | 武夷山元生泰生物科技有限公司 | A kind of ganoderma lucidum radix tetrastigme pulvis with treatment lung cancer effect and preparation method thereof |
Non-Patent Citations (1)
Title |
---|
王承儒: "岩舒注射液联合化疗治疗晚期非小细胞肺癌36例疗效观察", 中国实用医药, vol. 08, no. 12, pages 40 - 41 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113599460A (en) * | 2021-09-24 | 2021-11-05 | 广州颐寿达生物科技有限公司 | Ganoderma lucidum composition for assisting in inhibiting tumors and preparation method thereof |
CN114272308A (en) * | 2022-02-19 | 2022-04-05 | 姚远平 | A Chinese medicinal composition for treating cancer, and its preparation method |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113144107A (en) | Traditional Chinese medicine for treating lung cancer and preparation method thereof | |
TWI611807B (en) | Composition for preventing cancer and treating cancer and intensifying the effects of other anticancer drugs | |
CN101711848B (en) | Chinese medicinal composition capable of adjunctively treating tumour | |
CN104940479A (en) | TCM composition for treating AD diseases | |
CN108434399A (en) | A kind of Chinese medicine composition and preparation method of anti-curing oncoma | |
CN104857435A (en) | Chinese herbal compound composition with antineoplastic activity as well as preparation method and application thereof | |
CN105999096A (en) | Composition for enhancing immunity and application | |
CN103933541B (en) | A kind of glutathion anti-cancer composition | |
CN102225089B (en) | Pharmaceutical composition for treating cancers, pharmaceutical preparation as well as applications and production methods thereof | |
CN104435567A (en) | Traditional Chinese medicinal composition containing gynostemma pentaphyllum for treating gout | |
Hu et al. | Daphne genkwa: Ethnopharmacology, phytochemistry and pharmacology of an important traditional Chinese medicine | |
CN105749156B (en) | A kind of Chinese medicine composition and preparation method thereof for treating syndrome of dampness-heat stagnating in spleen | |
KR20160086457A (en) | Composition comprising alcohol extract of GamiBangkeehwangkeetang for preventing and treating a rheumatoid arthritis | |
CN115531457B (en) | A Chinese medicinal composition with anti-tumor function, and its preparation method | |
CN109331031A (en) | A kind of new application of chonglou saponin VII | |
CN1314425C (en) | Chinese traditional medicine for treating rheumatoid arthritis | |
CN103191268B (en) | Traditional Chinese medicinal composition for treating lung cancer | |
CN105617319A (en) | Preparation method of traditional Chinese medicine composition for treating acute cholecystitis | |
CN103751239B (en) | A kind of preparation method and applications of Radix Et Caulis Acanthopanacis Senticosi total glucosides and manyprickle acanthopanax general glycosides formulation | |
CN103655822B (en) | Anti-tumor drug as well as preparation method and application thereof | |
CN108096289A (en) | A kind of antrodia capsule formula and production method | |
CN103239569B (en) | Application of viola diffusa in preparation of medicine for treating viral hepatitis | |
CN112089783B (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing or/and treating obesity | |
CN102327421B (en) | Blood-activating and vitality circulation-promoting Chinese medicinal preparation for treating esophageal cancer and preparation method thereof | |
CN109718280B (en) | A Chinese medicinal composition for treating female climacteric syndrome, and its preparation method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210723 |